North­eastern Uni­ver­sity sci­en­tist Vladimir Torchilin is the world’s second-​​most pro­lific researcher in phar­ma­cology and tox­i­cology, according to Times Higher Edu­ca­tion, a London-​​based inter­na­tional publication.

Times Higher Edu­ca­tion ranked the world’s top sci­en­tists in the field according to pub­li­ca­tion counts and cita­tion data com­piled over the last 10 years by infor­ma­tion com­pany Thomson Reuters.

Torchilin, Dis­tin­guished Pro­fessor of phar­ma­ceu­tical sci­ences, pub­lished 56 papers in phar­ma­cology and tox­i­cology jour­nals between Jan­uary 2000 and August 2010. The papers attracted an average of 56.8 citations.

Only a bio­mol­e­c­ular chemist at the National Research Council in Italy earned more cita­tions per paper.

To qualify for inclu­sion on the list, researchers must have ranked in the top 1 per­cent of their field in terms of total cita­tions and pub­lished at least 50 papers within the last decade.

Of his 56 pharmacology-​​related papers, Torchilin pub­lished 11 highly cited and “hot” papers.

Highly cited papers rank in the top 1 per­cent for total cita­tions when com­pared with papers pub­lished in the same field during the same year. Hot papers are no more than two years old and rank in the top .1 per­cent in terms of total cita­tions when com­pared with papers pub­lished in the same field during the same two-​​month time frame.

This is an unex­pected suc­cess,” says Torchilin, who esti­mates that he’s written more than 100 papers over the last 10 years, many of which were pub­lished in phys­ical chem­istry and bio­chem­ical journals.

There are a lot of good researchers who write papers that I like very much, but it seems that my arti­cles appear a frac­tion of a step sooner than others on more occa­sions,” he says.

Torchilin directs the Center for Phar­ma­ceu­tical Biotech­nology and Nanomed­i­cine and spear­heads Northeastern’s Center for Trans­la­tional Cancer Nanomed­i­cine, which was funded by a five-​​year, $13.5 mil­lion grant from the National Insti­tutes of Health’s National Cancer Institute.

His cur­rent work, which dove­tails with Northeastern’s focus on use-​​inspired research that solves global chal­lenges in health, secu­rity and sus­tain­ability, focuses on devel­oping drugs that target spe­cific organelles inside human cells in order to max­i­mize the ther­a­peutic outcome.